{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:22:18Z","timestamp":1787008938399,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring provides important guidance for treatment of patients with inflammatory bowel disease (IBD) and could help to early identify treatment failure. This study aimed to validate a finger prick\u2013based capillary blood sampling technique to measure biological trough levels and C-reactive protein (CRP) and evaluate patient performance and -support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective cohort study, patients with IBD receiving infliximab (IFX) or vedolizumab (VEDO) therapy performed finger prick\u2013based capillary blood sampling at home. Additionally, blood was collected through routinely performed in-hospital venepuncture prior to biological infusion. IFX, VEDO, and CRP concentrations were measured by enzyme-linked immunosorbent assay. The concordance between methods was statistically evaluated and a survey was conducted to assess practicality and patient support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 81 patients (46 IFX, 35 VEDO) were enrolled. Mean differences between both methods were 0.42 (95% confidence interval, -1.74 to 2.58) \u03bcg\/mL for IFX and 0.72 (95% confidence interval, -5.50 to 6.94) \u03bcg\/mL for VEDO. Passing-Bablok regressions demonstrated no evidence for systematic or proportional biases. Venous and capillary IFX (\u03c1\u2005=\u20050.96, P\u2005&amp;lt;\u2005.001) and VEDO (\u03c1\u2005=\u20050.97, P\u2005&amp;lt;\u2005.001) levels strongly correlated and showed high intermethod agreement (Cohen\u2019s kappa: IFX = 0.82; VEDO = 0.94). Similarly, venous and capillary CRP levels were strongly correlated (\u03c1\u2005=\u20050.99, P\u2005&amp;lt;\u2005.001). Most patients (&amp;gt;95%) were able to successfully perform the self-sampling at home without prior instructions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study clinically validated a finger prick\u2013based capillary blood self-sampling technique allowing concomitant home monitoring of biological levels and CRP for patients with IBD, who reported substantial support, tolerability, and practicality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izad103","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:54:23Z","timestamp":1685728463000},"page":"325-335","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-5694","authenticated-orcid":false,"given":"Antonius T","family":"Otten","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig H","family":"van der Meulen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Steenhuis","sequence":"additional","affiliation":[{"name":"Biologics Laboratory, Sanquin Diagnostic Services , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris C","family":"Loeff","sequence":"additional","affiliation":[{"name":"Biologics Laboratory, Sanquin Diagnostic Services , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan J","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G W","family":"Kosterink","sequence":"additional","affiliation":[{"name":"Department of PharmacoTherapy, Epidemiology and Economy, Groningen Research Institute of Pharmacy, University of Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderik W","family":"Frijlink","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn C","family":"Visschedijk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-3821","authenticated-orcid":false,"given":"Arno R","family":"Bourgonje","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2024030114274640600_CIT0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clim.2018.03.004","article-title":"Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies","volume":"206","author":"Katsanos","year":"2018","journal-title":"Clin Immunol."},{"issue":"8","key":"2024030114274640600_CIT0002","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024030114274640600_CIT0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024030114274640600_CIT0004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/flgastro-2016-100685","article-title":"Use of anti-TNF drug levels to optimise patient management","volume":"7","author":"Papamichael","year":"2016","journal-title":"Frontline Gastroenterol."},{"issue":"9","key":"2024030114274640600_CIT0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024030114274640600_CIT0006","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2024030114274640600_CIT0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut."},{"issue":"8","key":"2024030114274640600_CIT0008","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis."},{"key":"2024030114274640600_CIT0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmed.2020.00123","article-title":"Serum biomarkers for inflammatory bowel disease","volume":"7","author":"Chen","year":"2020","journal-title":"Front Med (Lausanne)."},{"issue":"5","key":"2024030114274640600_CIT0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","article-title":"C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn\u2019s disease: a post-hoc analysis from ACCENTI","volume":"35","author":"Reinisch","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024030114274640600_CIT0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn\u2019s disease patients predicts nonresponse to infliximab treatment","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2024030114274640600_CIT0012","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/PPA.S303279","article-title":"Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review","volume":"15","author":"Overton","year":"2021","journal-title":"Patient Prefer Adherence."},{"issue":"16","key":"2024030114274640600_CIT0013","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1021\/ac5022562","article-title":"Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis","volume":"86","author":"Denniff","year":"2014","journal-title":"Anal Chem."},{"issue":"2","key":"2024030114274640600_CIT0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/FTD.0000000000000686","article-title":"Monitoring of adalimumab concentrations at home in patients with inflammatory bowel disease using dried blood samples","volume":"l42","author":"Berends","year":"2020","journal-title":"Ther Drug Monit."},{"issue":"11","key":"2024030114274640600_CIT0015","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet."},{"issue":"11","key":"2024030114274640600_CIT0016","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4155\/bio-2018-0010","article-title":"Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra\u00ae microsampler vs dried blood spot","volume":"10","author":"Bloem","year":"2018","journal-title":"Bioanalysis."},{"issue":"3","key":"2024030114274640600_CIT0017","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/13524585221136448","article-title":"Fingerprick blood samples to measure serum natalizumab concentrations","volume":"29","author":"Toorop","year":"2022","journal-title":"Mult Scler."},{"issue":"8","key":"2024030114274640600_CIT0018","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024030114274640600_CIT0019","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab induces endoscopic and histologic remission in patients with Crohn\u2019s disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology."},{"issue":"4","key":"2024030114274640600_CIT0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1365-2567.2003.01681.x","article-title":"Rat C-reactive protein activates the autologous complement system","volume":"109","author":"Padilla","year":"2003","journal-title":"Immunology."},{"issue":"1","key":"2024030114274640600_CIT0021","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MPG.0000000000002906","article-title":"Infliximab level between venous and capillary blood using novel device strongly correlate in paediatric inflammatory bowel disease patients","volume":"72","author":"Zijlstra","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"2","key":"2024030114274640600_CIT0022","doi-asserted-by":"crossref","first-page":"20150039","DOI":"10.1515\/ijb-2015-0039","article-title":"Sample size for assessing agreement between two methods of measurement by Bland-Altman method","volume":"12","author":"Lu","year":"2016","journal-title":"Int J Biostat."},{"issue":"8476","key":"2024030114274640600_CIT0023","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet."},{"issue":"11","key":"2024030114274640600_CIT0024","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"8","key":"2024030114274640600_CIT0025","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024030114274640600_CIT0026","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNF-\u03b1 for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin Biol Ther."},{"issue":"1","key":"2024030114274640600_CIT0027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease - algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2024030114274640600_CIT0028","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2024030114274640600_CIT0029","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MOG.0000000000000536","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug","volume":"35","author":"Papamichael","year":"2019","journal-title":"Curr Opin Gastroenterol."},{"issue":"4","key":"2024030114274640600_CIT0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2024030114274640600_CIT0031","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024030114274640600_CIT0032","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/flgastro-2018-101054","article-title":"Recent advances in monoclonal antibody therapy in IBD: practical issues","volume":"10","author":"Tamilarasan","year":"2019","journal-title":"Frontline Gastroenterol."},{"issue":"1","key":"2024030114274640600_CIT0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","article-title":"Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review","volume":"52","author":"Martelli","year":"2017","journal-title":"J Gastroenterol."},{"issue":"12","key":"2024030114274640600_CIT0034","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1080\/17425255.2021.2027367","article-title":"Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies","volume":"17","author":"Papamichael","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"4","key":"2024030114274640600_CIT0035","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024030114274640600_CIT0036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.16852","article-title":"Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease","volume":"56","author":"Roblin","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"2024030114274640600_CIT0037","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/apt.16927","article-title":"Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease","volume":"55","author":"Bergqvist","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024030114274640600_CIT0038","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ecco-jcc\/jjab128","article-title":"Patient-led remote IntraCapillary pharmacoKinetic sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease","volume":"16","author":"Chee","year":"2022","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad103\/50509841\/izad103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/3\/325\/56732102\/izad103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/3\/325\/56732102\/izad103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:21:26Z","timestamp":1709288486000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/3\/325\/7188941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,2]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad103","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,6,2]]}}}